KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $141.7 million.

  • Bio-Rad Laboratories' Other Accumulated Expenses fell 373.64% to $141.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $141.7 million, marking a year-over-year decrease of 373.64%. This contributed to the annual value of $141.7 million for FY2025, which is 373.64% down from last year.
  • According to the latest figures from Q4 2025, Bio-Rad Laboratories' Other Accumulated Expenses is $141.7 million, which was down 373.64% from $127.8 million recorded in Q3 2025.
  • Bio-Rad Laboratories' Other Accumulated Expenses' 5-year high stood at $212.7 million during Q2 2022, with a 5-year trough of $127.8 million in Q3 2025.
  • Its 5-year average for Other Accumulated Expenses is $159.7 million, with a median of $158.3 million in 2021.
  • As far as peak fluctuations go, Bio-Rad Laboratories' Other Accumulated Expenses surged by 3728.69% in 2022, and later crashed by 2184.71% in 2023.
  • Bio-Rad Laboratories' Other Accumulated Expenses (Quarter) stood at $127.9 million in 2021, then surged by 32.6% to $169.6 million in 2022, then decreased by 4.74% to $161.6 million in 2023, then dropped by 8.91% to $147.2 million in 2024, then dropped by 3.74% to $141.7 million in 2025.
  • Its Other Accumulated Expenses was $141.7 million in Q4 2025, compared to $127.8 million in Q3 2025 and $175.0 million in Q2 2025.